Rockefeller Capital Management L.P. Has $10.63 Million Stake in Progyny, Inc. (NASDAQ:PGNY)

Rockefeller Capital Management L.P. lowered its stake in Progyny, Inc. (NASDAQ:PGNY) by 35.1% in the third quarter, Holdings Channel reports. The fund owned 633,201 shares of the company’s stock after selling 341,999 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Progyny were worth $10,627,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Public Sector Pension Investment Board bought a new position in Progyny in the 3rd quarter valued at approximately $2,792,000. Quantbot Technologies LP acquired a new position in shares of Progyny during the third quarter worth $2,187,000. Crestwood Capital Management L.P. lifted its stake in shares of Progyny by 17.9% in the 3rd quarter. Crestwood Capital Management L.P. now owns 436,081 shares of the company’s stock valued at $7,309,000 after acquiring an additional 66,331 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Progyny during the 3rd quarter valued at $1,613,000. Finally, Algert Global LLC grew its position in Progyny by 138.7% during the 3rd quarter. Algert Global LLC now owns 184,885 shares of the company’s stock worth $3,099,000 after acquiring an additional 107,432 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Price Performance

NASDAQ PGNY opened at $15.59 on Tuesday. The stock has a market capitalization of $1.33 billion, a P/E ratio of 26.88, a P/E/G ratio of 1.80 and a beta of 1.44. The business has a 50 day simple moving average of $15.82 and a 200 day simple moving average of $22.15. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period last year, the business earned $0.16 EPS. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. Equities analysts expect that Progyny, Inc. will post 0.58 earnings per share for the current year.

Analysts Set New Price Targets

PGNY has been the topic of a number of recent research reports. Leerink Partnrs lowered Progyny from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Barclays reduced their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $17.00 price target (down from $22.00) on shares of Progyny in a research report on Monday. Canaccord Genuity Group reduced their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Progyny has a consensus rating of “Hold” and a consensus target price of $25.00.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.